Kiniksa Pharmaceuticals Ltd (KNSA)vsEli Lilly and Company (LLY)
KNSA
Kiniksa Pharmaceuticals Ltd
$52.99
-1.60%
HEALTHCARE · Cap: $4.08B
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 9520% more annual revenue ($65.18B vs $677.56M). LLY leads profitability with a 31.7% profit margin vs 8.7%. LLY trades at a lower P/E of 37.0x. LLY earns a higher WallStSmart Score of 78/100 (B+).
KNSA
Buy51
out of 100
Grade: C-
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.8%
Fair Value
$202.90
Current Price
$52.99
$149.91 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.0% year-over-year
Earnings expanding 550.0% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 65.0% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 58.2x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
KNSA is growing revenue faster at 65.0% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 51/100), backed by strong 31.7% margins and 42.6% revenue growth. KNSA offers better value entry with a 77.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is a cutting-edge biopharmaceutical company dedicated to addressing high unmet medical needs through the development of innovative therapies. The company's leading candidate, KPL-404, is a targeted monoclonal antibody aimed at modulating B and T lymphocyte activity, potentially transforming treatment options for autoimmune disorders. Kiniksa's robust pipeline, underscored by ongoing clinical trials and strategic collaborations, positions it for significant growth and expansion within the pharmaceutical landscape. With a focus on scientific innovation and a commitment to redefining treatment paradigms, Kiniksa presents a compelling opportunity for institutional investors seeking exposure in the biopharmaceutical sector.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?